RBC raises Acadia Pharmaceuticals stock price target on Daybue growth
RBC Capital raised its price target for Acadia Pharmaceuticals (ACAD) to $38, citing strong Daybue uptake and growth potential. The firm expects European launch and pipeline readouts to drive future sales. Acadia reported Q3 2026 earnings of $0.31 per share, beating estimates, with revenue of $342 million. Daybue sales grew 39% YoY to $140 million, while Nuplazid sales increased 12% to $202 million. The company narrowed its 2026 revenue guidance to $1.265B-$1.295B.
How this was made
The 30-second read
Why it matters
Earnings beat and target raise provide a clear catalyst for short‑term upside.
Market read
The news is material for traders focused on biotech equities and could drive ACAD higher in the near term.
What to watch
Potential regulatory or reimbursement risks for DAYBUE in new markets.
Background
Acadia Pharmaceuticals reported Q3 2026 results, beating estimates, and RBC raised its price target.
Ticker impact
RBC raised its price target for Acadia Pharmaceuticals to $38 and reported Q3 2026 earnings beat with $140M DAYBUE sales and $202M NUPLAZID sales.
likely upward pressure as investors price in the earnings beat and higher target
The combination of a 39% sales increase for DAYBUE, a beat on EPS, and a price‑target hike provides fresh, material information that can move the stock.
Market effects
Strong biotech earnings may lift peer neuro‑psychiatric drug makers.
Positive for US biotech sector.
Limited to biotech investors; no broad market effect.
Counterpoint
If the sales growth is not sustainable, the stock could face a pull‑back despite the upgrade.
Key entities
- companyAcadia Pharmaceuticals Inc.
US‑listed biotech firm (NASDAQ:ACAD).
- analystRBC Capital Markets
Raised price target to $38.
